Browse Erythropoietin, Recombinant topic

Subtopics (19)

Articles

1-40 out of 40 article(s)

Title	Author	Type	Date	Words
Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations.			Dec 19, 2012	1052
US Nephrologists Expect Rapid Adoption of the United States' First Biosimilars - Epoetin Alfa.			Oct 8, 2012	544
Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies in Dialysis Patients at the American Society of Nephrology's Kidney Week 2011.		Clinical report	Nov 11, 2011	2621
Medication adherence in patients with chronic kidney disease.	Raymond, Colette B.; Wazny, Lori D.; Sood, Amy R.	Survey	Apr 1, 2011	3120
Epogen and Procrit recalled due to particulate matter in vials.		Brief article	Oct 5, 2010	216
Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications / Rhesus hemolitik hastalikli bir vakada hiporejeneratif anemi ve asiri demir yuklenmesi: nadir gelisen komplikasyona terapotik yaklasim.	Demircioglu, Fatih; Sozmen, Sule Caglayan; Yilmaz, Sebnem; Oren, Hale; Arslan, Nur; Kumral, Abdullah		Sep 1, 2010	2922
United States : Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients.			Jul 27, 2010	288
Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients.			Jul 26, 2010	871
FDA announces new safety plan for Erythropoiesis-Stimulating Agents.			Feb 23, 2010	407
FDA Announces New Safety Plan for Agents Used to Treat Chemotherapy-Related Anemia.			Feb 16, 2010	738
Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA.			Feb 16, 2010	2223
Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA.			Feb 16, 2010	1443
Oncology implications for exercise and rehabilitation.	Billek-Sawhney, Barbara; Wells, Chris L.	Report	Dec 22, 2009	6050
Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide[TM] Increased Hemoglobin in Dialysis Patients.			Oct 30, 2009	1059
Appeals Court affirms patent infringement rulings against Roche's peg-EPO product.			Aug 1, 2009	344
Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes.	Wazny, Lori D.; Raymond, Colette B.; Do, Michelle K.; Skwarchuk, Dan E.	Report	Jul 1, 2009	2508
US health officials said on Friday they were reviewing a higher rate of deaths among patients treated with a Johnson & Johnson (New Brunswick NJ) anemia drug in a German study of stroke patients.		Brief article	Oct 6, 2008	273
Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia.			Apr 4, 2008	714
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R).			Mar 7, 2008	1145
NeuroDigm's Model Reveals the Reversal of Chronic Pain.			Feb 4, 2008	372
Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.	Raymond, Colette B.; Wazny, Lori D.; Vercaigne, Lavern M.; Lesperance, Esther M.; Skwarchuk, Dan E.;		Jan 1, 2008	3627
Stop ESAs in nonresponders after 6-8 weeks.	Brunk, Doug		Jan 1, 2008	663
NCCN Updates Cancer- and Treatment-Related Anemia Guidelines.			Dec 20, 2007	665
Mayo clinic study links anemia drugs to leukemia risk.			Dec 17, 2007	486
Amgen Announces Updates to the U.S. Prescribing Information for ESAs.			Nov 8, 2007	2229
Jury Rules Roche Infringes Amgen's EPO Patents.			Oct 23, 2007	232
TWI Successfully Defends Patent for Clearweld(R) Laser Welding Technology.			Oct 9, 2007	507
U.S. lawmakers asked Johnson & Johnson (New Brunswick NJ) and Amgen Inc. (Thousand Oaks CA) to suspend all consumer advertising of their anemia medications for cancer patients until after U.S. regulators complete their safety review.		Brief article	Mar 26, 2007	140
Amgen v. HMR: a case for deference in claim construction.	Brown, Andrew S.		Mar 22, 2007	10011
FDA strengthens safety information for ESAs.			Mar 12, 2007	424
Epoetin boosts quality of life in HIV patients.	Zoler, Mitchel L.		Feb 1, 2005	545
Studies eying erythropoietin's effects on survival, CV events.	Mechcatie, Elizabeth		Jun 15, 2004	643
Detection of recombinant human erythropoietin in urine by isoelectric focusing.	Breidbach, Andreas; Catlin, Don H.; Green, Gary A.; Tregub, Inna; Truong, Henry; Gorzek, Jeffrey		Jun 1, 2003	4443
Epoetin alfa may keep breast ca patients sharp. (Preventing Cognitive Decline).	Jancin, Bruce		May 1, 2003	359
Epoetin alfa may keep breast cancer patients sharp. (Prevents Cognitive Dysfunction).	Jancin, Bruce		Apr 1, 2003	303
Cardiac troponin T and creatine kinase MB content in skeletal muscle of the uremic rat.	Fredericks, Salim; Murray, Joanne F.; Carter, Nicholas D.; Chesser, Alistair M.S.; Papachristou, Sta	Clinical report	Jun 1, 2002	7130
Contaminated Epoetin Alfa.	Mitchell, Steve		Jul 1, 2001	224
Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98.	Greer, Joel W.; Milam, Roger A.; Eggers, Paul W.		Mar 22, 1999	3544
European patent office upholds Kirin-Amgen's European patent on recombinant erythropoietin.			Nov 21, 1994	132
A review of the first year of Medicare coverage of erythropoietin.	Griffiths, Robert I.; Powe, Neil R.; Greer, Joel; De Lissovoy, Gregory; Anderson, Gerard F.; Whelton		Mar 22, 1994	7323